RxDoctor Payments Data

Erin Winter, MD

Family Medicine · Altamont, NYNPI 1801952379

Payments from drug & device makers

$6,929in general payments, 2019–2025

Across 314 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$1K
  • AbbVie$1K
  • Johnson & Johnson$849
  • Sun Pharmaceutical Industries Inc.$391
  • Incyte Corporation$383
  • Sanofi$316
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$1,44021%
  • Food & beverage$5,20175%
  • Education$2884%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,929 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$140,322
Medicare patients
618
Services billed
2,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab125$469,238
XolairOmalizumab52$207,257
StelaraUstekinumab11$202,567
Dupixent SyringeDupilumab32$117,799
Cosentyx Sensoready (2 Pens)Secukinumab12$87,129
RinvoqUpadacitinib13$73,941
OtezlaApremilast12$57,961
ZoryveRoflumilast28$23,316
VtamaTapinarof11$14,684
Metronidazole60$6,043
Clobetasol Propionate99$4,351
Azelaic Acid33$4,284
Ketoconazole192$4,198
Tacrolimus34$3,631
Triamcinolone Acetonide151$2,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$849$202,56711 claims
AbbVieRinvoq$1,227$73,94113 claims
AmgenOtezla$80$57,96112 claims
Arcutis Biotherapeutics, Inc.Zoryve$81$23,31628 claims
Dermavant Sciences, Inc.Vtama$279$14,68411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Altamont

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →